Alkermes (ALKS) Retained Earnings (2011 - 2026)
Alkermes' (ALKS) quarterly Retained Earnings came in at -$801.3 million in Q1 2026, down 54970.38% year-on-year from N/an in Q1 2025, and down 38055.9% on a QoQ basis from -$2.1 million in Q4 2025.
Alkermes (ALKS) Retained Earnings (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Retained Earnings data on file, last reported at -$801.3 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 54970.38% year-over-year to -$801.3 million in Q1 2026; TTM through Mar 2026 was -$801.3 million, a 54970.38% decrease from a year earlier, with the FY2025 full-year figure at -$2.1 million, down 6.76% from the prior year.
- Retained Earnings for Q1 2026 stood at -$801.3 million, down from -$2.1 million in the prior quarter.
- Over the last five years, Retained Earnings for ALKS reached as high as $425000.0 in Q3 2024 and fell as low as -$1.6 billion in Q2 2022.
- Historically, Retained Earnings has averaged -$474.7 million across 5 years, with a median of -$8.2 million in 2022.
- Across the five-year window, Retained Earnings surged 100.03% in 2024 and tumbled 54970.38% in 2026, its largest moves.
- Year by year, Retained Earnings stood at -$10.9 million in 2022, then slumped by 12238.4% to -$1.3 billion in 2023, then surged by 99.85% to -$2.0 million in 2024, then slipped by 6.76% to -$2.1 million in 2025, then slumped by 38055.9% to -$801.3 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$801.3 million in Q1 2026, -$2.1 million in Q4 2025, and -$1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -801.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -801.27 Mn |
| Dec 31, 2025 | -2.10 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | -1.97 Mn |
| Sep 30, 2024 | 425,000.00 |
| Jun 30, 2024 | -3.59 Mn |
| Mar 31, 2024 | -1.31 Bn |
| Dec 31, 2023 | -1.34 Bn |
| Sep 30, 2023 | -1.46 Bn |
| Jun 30, 2023 | -1.50 Bn |
| Mar 31, 2023 | -8.13 Mn |
| Dec 31, 2022 | -10.89 Mn |
| Sep 30, 2022 | -12.84 Mn |
| Jun 30, 2022 | -1.61 Bn |
| Mar 31, 2022 | -8.23 Mn |
| Dec 31, 2021 | -3.72 Mn |
| Sep 30, 2021 | -2.47 Mn |
| Jun 30, 2021 | -1.51 Bn |